Endpoints News 18 dic 2025 Daiichi and Merck's I-Dxd lung cancer study faces partial hold due to deaths
Endpoints News 18 dic 2025 After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset
Endpoints News 18 dic 2025 Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting